打开APP

Inovio DNA癌症疫苗INO-1400可导致动物体内癌细胞死亡

  1. INO-1400
  2. Inovio

来源:生物谷 2013-07-29 18:07

2013年7月26日讯 /生物谷BIOON/ --由Inovio医药公司研发的DNA癌症疫苗INO-1400在动物实验中能有效引起癌细胞死亡提高动物存活率。Inovio公司利用hTERT DNA疫苗打破机体免疫系统的自身免疫耐受,促进T细胞分化杀伤肿瘤细胞。Inovio公司也在猴子(与人类TERT有96%相似性)身上接种了该疫苗进行研究。下一步公司计划于2014年进行临床研究。

2013年7月26日讯 /生物谷BIOON/ --由Inovio医药公司研发的DNA癌症疫苗INO-1400在动物实验中能有效引起癌细胞死亡提高动物存活率。Inovio公司利用hTERT DNA疫苗打破机体免疫系统的自身免疫耐受,促进T细胞分化杀伤肿瘤细胞。Inovio公司也在猴子(与人类TERT有96%相似性)身上接种了该疫苗进行研究。下一步公司计划于2014年进行临床研究。(生物谷Bioon.com)

详细英文报道:

A DNA cancer vaccine developed by Blue Bell, PA-based Inovio Pharmaceuticals ($INO) caused tumor cell death and increased the rate of survival in animal studies.

Using the company's adaptive electroporation delivery technology, the hTERT DNA vaccine broke the immune system's tolerance to its self-antigens and induced T cells with a tumor-killing function. High levels of human telomerase reverse transcriptase, also known as hTERT, are detected in over 85% of human cancers.

Mice that were given Inovio's hTERT DNA vaccine and then exposed to a cancerous tumor experienced delayed tumor growth and longer overall survival compared with mice that were not vaccinated. In mice that were first exposed to a tumor and then treated, the vaccine was able to kill some of the targeted cancer cells expressing the hTERT antigen while leaving normal cells that did not express the hTERT antigen intact. The treated mice had smaller tumors and also longer overall survival than untreated mice.

Inovio also tested the vaccine in monkeys, where TERT is 96% similar to human TERT, making it a highly relevant human model. In monkeys, the DNA vaccine elicited strong and broad TERT-specific immune responses and demonstrated the potential to eliminate tumor cells. The research appears in the American Association for Cancer Research journal Cancer Immunology Research.

The field of cancer vaccines has seen its ups and downs over the years, and lately there has been a renewed interest in trying to develop therapeutic cancer vaccines. Inovio plans to advance its synthetic hTERT cancer vaccine, INO-1400, into clinical trials in 2014.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->